XstalBio Introduces CentuRecon

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-09-02-2013
Volume 37
Issue 9

CentuRecon enables dry formulations of therapeutic proteins to quickly be prepared for injection at high concentration.

CentuRecon, a patented reconstitution technology, decreases the preparation time of high concentration protein solutions from dry powder formulations and makes delivery faster and safer, according to the company. CentuRecon enables dry formulations of therapeutic proteins to quickly be prepared for injection at high concentration and produces foam-free solutions that maximize the deliverable dose. CentuRecon is compatible with standard lyophilized formulations and diluents and with normal vials, cartridges, or dual-chamber syringes. It can be used for very high concentration and/or viscous solutions that may need to be delivered with injection devices.

XstalBio

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Related Content